Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,302 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06975410RecruitingPhase 1/Phase 2
Trial of YH32364 for EGFR-positive solid tumors
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
SeoulAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07098299RecruitingPhase 1
Metformin with chemotherapy or immunotherapy for advanced solid tumors
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
Bay City, MichiganAges 18 years+ - NCT07589205RecruitingPhase 1
Testing IBI3028 for Advanced Solid Tumors
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT03454035RecruitingPhase 1
Combination of two study drugs for advanced pancreatic and other solid tumors
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Chapel Hill, North CarolinaAges 18–99 - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT05341492RecruitingEarly Phase 1
CAR-T therapy for EGFR/B7H3-positive lung and triple-negative breast cancer
This early-phase trial tests CAR-T cells designed to find and attack tumors that show EGFR or B7H3 markers. It may help people with advanced lung cancer or triple-negative breast cancer after standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06382948RecruitingPhase 3
Elacestrant and everolimus for ESR1-mutant advanced breast cancer
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
InnsbruckAges 18 years+ - NCT06430502Recruiting
Cancer vaccine plus immunotherapy for advanced solid tumors
This trial tests a cancer vaccine (called TTV) combined with a PD-1 inhibitor (a type of immunotherapy) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this new combination helps shrink tumors or slow cancer growth.
Wuxi, JiangsuAges 18–85 - NCT07387081RecruitingPhase 2
Study of LM-24C5 for advanced solid tumors
This trial tests a new drug, LM-24C5, for people with advanced solid tumors that have come back or not responded to treatment. It may be an option if your tumor has a specific marker called CEACAM5.
Fuzhou, FujianAges 18–80 - NCT07292038RecruitingPhase 1
Testing NM6603 in advanced solid tumors
This study tests an experimental oral drug called NM6603 in people with advanced solid tumors, especially colorectal cancer or triple-negative breast cancer. It aims to find a safe dose and see how the drug works in the body.
Xiamen, FujianAges 18–75 - NCT06298084RecruitingPhase 1/Phase 2
HER3-DXd for Advanced Breast Cancer After T-DXd
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
Villejuif, FranceAges 18 years+ - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07205718RecruitingPhase 1/Phase 2
Study of TAK-188 for advanced solid tumors
This trial tests a new medicine, TAK-188, for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
Santa Monica, CaliforniaAges 18 years+ - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT06678659RecruitingPhase 1/Phase 2
Study of REC-1245 for advanced solid tumors and lymphoma
This trial tests a new drug, REC-1245, for people with advanced solid tumors or certain lymphomas that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow disease progression.
Duarte, CaliforniaAges 12 years+ - NCT06248411RecruitingPhase 1
Study of KK2260 for advanced solid tumors
This study tests a new experimental drug, KK2260, for people with advanced or advanced solid tumors, especially esophageal cancer and certain head and neck cancers. The goal is to see if the drug is safe and helps shrink or control the cancer.
Nagoya, Aichi-kenAges 18 years+ - NCT07047365RecruitingPhase 3
New drug for HER2-positive advanced breast cancer
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Bengbu, AnhuiAges 18–75 - NCT05410717RecruitingPhase 1
CAR-NK cell therapy for certain solid tumors
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
Guangzhou, GuangdongAges 18–75 - NCT05205850RecruitingPhase 1/Phase 2
RC118 for solid cancers with Claudin 18.2 on tumor cells
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT07596693RecruitingPhase 1
KXV01 injection for advanced solid tumors
This early-stage trial tests KXV01, a personalized cancer treatment made from your own immune cells, for advanced solid tumors that have not responded to standard treatment. The goal is to see if it can help control your cancer and learn about its safety.
ShanghaiAges 18–70 - NCT06959615RecruitingPhase 1/Phase 2
Study of JAB-23E73 for KRAS-Altered Advanced Tumors
This trial tests an experimental pill (JAB-23E73) for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink or slow the growth of these cancers.
Hefei, AnhuiAges Any age
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,302 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.